Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Untch

Showing results (161-170 of 377) with videos related to

Pageof 38
Sort By:
Breast Cancer Research : BCR|February 9, 2013
HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancerCarsten Denkert, Jens Huober, Sibylle Loibl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2010
First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trialMichael Untch, Michael Muscholl, Sergei Tjulandin, et al.
Annals of Surgical Oncology|April 18, 2014
Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44)Bernd Gerber, Gunter von Minckwitz, Holger Eidtmann, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2020
Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trialsGustavo Werutsky, Michael Untch, Claus Hanusch, et al.
Breast Care (Basel, Switzerland)|August 12, 2022
Practice-Changing Perspectives regarding Systemic Therapy in Early Breast Cancer: Opinions of German Experts regarding the 17th St. Gallen International Consensus ConferenceCornelia Kolberg-Liedtke, Diana Lüftner, Sara Y Brucker, et al.
Breast Cancer Research : BCR|September 24, 2024
On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancerBruno Valentin Sinn, Katharina Sychra, Michael Untch, et al.
Archives of Gynecology and Obstetrics|May 27, 2023
Th2/Th17 cell associated cytokines found in seroma fluids after breast cancer surgeryNicole Pochert, Mariella Schneider, Melitta B Köpke, et al.
Breast (Edinburgh, Scotland)|November 28, 2016
Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy - Results from the multi-center SENTINA trialLukas Schwentner, Gisela Helms, Valentina Nekljudova, et al.
Oncology Research and Treatment|November 17, 2024
Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B TrialManfred Welslau, Karin Potthoff, Matthias Zaiss, et al.
Geburtshilfe Und Frauenheilkunde|June 25, 2021
Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus ConferenceMichael Untch, Peter A Fasching, Sara Y Brucker, et al.
Pageof 38

Showing results (161-170 of 377) with videos related to

Sort By:
Pageof 38
Breast Cancer Research : BCR|February 9, 2013
HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancerCarsten Denkert, Jens Huober, Sibylle Loibl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2010
First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trialMichael Untch, Michael Muscholl, Sergei Tjulandin, et al.
Annals of Surgical Oncology|April 18, 2014
Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44)Bernd Gerber, Gunter von Minckwitz, Holger Eidtmann, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2020
Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trialsGustavo Werutsky, Michael Untch, Claus Hanusch, et al.
Breast Care (Basel, Switzerland)|August 12, 2022
Practice-Changing Perspectives regarding Systemic Therapy in Early Breast Cancer: Opinions of German Experts regarding the 17th St. Gallen International Consensus ConferenceCornelia Kolberg-Liedtke, Diana Lüftner, Sara Y Brucker, et al.
Breast Cancer Research : BCR|September 24, 2024
On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancerBruno Valentin Sinn, Katharina Sychra, Michael Untch, et al.
Archives of Gynecology and Obstetrics|May 27, 2023
Th2/Th17 cell associated cytokines found in seroma fluids after breast cancer surgeryNicole Pochert, Mariella Schneider, Melitta B Köpke, et al.
Breast (Edinburgh, Scotland)|November 28, 2016
Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy - Results from the multi-center SENTINA trialLukas Schwentner, Gisela Helms, Valentina Nekljudova, et al.
Oncology Research and Treatment|November 17, 2024
Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B TrialManfred Welslau, Karin Potthoff, Matthias Zaiss, et al.
Geburtshilfe Und Frauenheilkunde|June 25, 2021
Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus ConferenceMichael Untch, Peter A Fasching, Sara Y Brucker, et al.
Pageof 38